### Boston Scientific Announces Results For Third Quarter Ended September 30, 2013

NATICK, Mass., Oct. 24, 2013 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) generated sales of \$1.735 billion and adjusted earnings per share of \$0.17 for the third quarter ended September 30, 2013. The company reported a \$5 million GAAP loss, or approximately \$0.00 per share.

#### Third quarter results and recent developments:

- Achieved third quarter sales of \$1.735 billion, representing 4 percent operational growth (constant currency basis, excluding divested businesses), and consistent with prior year sales on a reported basis.
- Delivered adjusted EPS of \$0.17, exceeding the high end of the company's adjusted EPS guidance range of \$0.14 to \$0.16.
- Continued above-market growth in the company's MedSurg businesses with global year-over-year revenue growth of 32 percent in Neuromodulation, 8 percent in Endoscopy and 8 percent in Urology/Women's Health, all on a constant currency basis.
- Improved performance in the company's Cardiac Rhythm Management and Interventional Cardiology businesses, with CRM achieving growth of 1 percent on a constant currency basis. The company's Peripheral Interventions business also continued to perform strongly with 7 percent growth on a constant currency basis.
- · Continued global expansion with combined year-over-year growth of 29 percent in Brazil, Russia, India and China, all on a constant currency basis.
- Reinforced the company's ongoing commitment to advancing science in Asia-Pacific by opening the Boston Scientific Institute for Advancing Science
  (IAS) and new Innovation Center in China.
- Completed a previously announced public offering of senior notes and entered into a term loan facility to refinance 1.45 billion of existing public debt.
- Approved 2014 Restructuring Program, continuing the process of evolving the company's business model to address changing global marketplace dynamics. The program is expected to generate gross annual savings of \$150 million to \$200 million exiting 2015.
- Generated operating cash flow of \$250 million and used \$75 million to repurchase approximately 6.8 million shares under the company's existing share repurchase authorization.

"We are pleased with our strong overall results and the momentum we are building globally in a dynamic healthcare environment," said Mike Mahoney, Boston Scientific president and chief executive officer. "We accelerated our operational performance in the quarter while enhancing our ability to deliver meaningful innovation to our customers and their patients."

#### Worldwide sales for the third quarter:

		Months E ptember (				% Cha	nge	
in millions	2013		2012	As Reported Basis	Les	ss: Impact of Currency	Constant Currency Basis	
Interventional Cardiology	\$ 472	\$	494	(4)%	\$	(13)	(2)%	(2)%
Peripheral Interventions	195		189	3%		(8)	(4)%	7%
Cardiovascular	667		683	(2)%		(21)	(3)%	1%
Cardiac Rhythm Management	464		462	1%		(5)	0%	1%
Electrophysiology	34		35	(3)%		(1)	(2)%	(1)%
Rhythm Management	498		497	0%		(6)	(1)%	1%
Endoscopy	322		310	4%		(11)	(4)%	8%
Urology/Women's Health	131		125	5%		(4)	(3)%	8%
Neuromodulation	115		88	32%		(1)	0%	32%
MedSurg	568		523	9%		(16)	(3)%	12%
Subtotal Core Businesses	1,733		1,703	2%		(43)	(2)%	4%
Divested Businesses	2		32	(95)%		_	0%	(95)%
Worldwide Net Sales	\$ 1,735	\$	1,735	0%	\$	(43)	(2)%	2%

Growth rates are based on actual, non-rounded amounts and may not recalculate precisely.

Sales growth rates that exclude the impact of changes in foreign currency exchange rates are not prepared in accordance with U.S. GAAP. An explanation of the company's use of these non-GAAP financial measures is included in the exhibits attached to this news release.

On a consolidated GAAP basis, net loss for the third quarter of 2013 was\$5 million, or \$0.00 per share. These results included acquisition-, litigation- and restructuring-related charges, and amortization and debt extinguishment expenses, of \$235 million (after-tax) or \$0.17 per share. Adjusted net income for the third quarter of 2013, excluding these net charges, was \$230 million, or \$0.17 per share.

On a consolidated GAAP basis, net loss for the third quarter of 2012 was\$664 million, or \$0.48 per share. These results included goodwill and other intangible asset impairment charges, acquisition- and divestiture- related net credits, restructuring- and litigation-related charges, discrete tax items and amortization expense, of \$885 million or \$0.64 per share. Adjusted net income for the third quarter of 2012, excluding these net charges, was\$221 million, or \$0.16 per share.

Boston Scientific also announces a 2014 Restructuring Program that is intended to build on the progress the company has made to execute in a changing global marketplace while further strengthening its operational effectiveness and supporting new growth investments. Key activities under the program include continued implementation of the company's ongoing Plant Network Optimization strategy, continued focus on driving operational efficiencies and ongoing business and commercial model changes.

The company estimates that the program will reduce gross annual pre-tax operating expenses by approximately\$150 million to \$200 million exiting 2015. The company expects a portion of program savings to be reinvested in strategic growth initiatives.

The company anticipates a gross reduction of 1,100 to 1,500 positions worldwide through a combination of employee attrition and targeted headcount reductions as the program is implemented. Program implementation is expected to result in total pre-tax charges of approximately \$175 million to \$225 million, with approximately \$160 million to \$210 million of these charges resulting in future cash outlays. Program activities are expected to be initiated in the fourth quarter of 2013 and are expected to be substantially completed by the end of 2015.

#### **Guidance for Fourth Quarter and Full Year 2013**

The company estimates sales for the fourth quarter of 2013 in a range of \$1.780 to \$1.830 billion. The company estimates earnings on a GAAP basis in a range of \$0.04 to \$0.08 per share. Adjusted earnings, excluding acquisition- and restructuring-related charges and amortization expense, are estimated in a range of \$0.18 to \$0.20 per share.

The company estimates sales for the full year 2013 in a range of \$7.085 to \$7.135 billion. The company estimates losses on a GAAP basis in a range of (\$0.13) to (\$0.09) per share. Adjusted earnings, excluding goodwill and intangible asset impairment charges, acquisition-, restructuring-, and litigation-related charges, divestiture-related net credits, debt extinguishment expense and amortization expense; are estimated in a range of \$0.69 to \$0.71 per share.

#### **Conference Call Information**

Boston Scientific management will be discussing these results with analysts on a conference call today a8:00 a.m. (ET). The company will webcast the call to interested parties through its website: <a href="www.bostonscientific.com">www.bostonscientific.com</a>. Please see the website for details on how to access the webcast. The webcast will be available for approximately one year on the Boston Scientific website.

#### **About Boston Scientific**

Boston Scientific transforms lives through innovative medical solutions that improve the health of patients around the world. As a global medical technology leader for more than 30 years, we advance science for life by providing a broad range of high performance solutions that address unmet patient needs and reduce the cost of healthcare. For more information, visit <a href="https://www.bostonscientific.com">www.bostonscientific.com</a> and connect on <a href="https://www.bostonscientific.com">Twitter</a> and <a href="https://www.bostonscientific.com">Facebook</a>.

#### **Cautionary Statement Regarding Forward-Looking Statements**

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1934. Forward-looking statements may be identified by words like "anticipate," "expect," "project," "believe," "plan," "estimate," "intend" and similar words. These forward-looking statements are based on our beliefs, assumptions and estimates using information available to us at the time and are not intended to be guarantees of future events or performance. These forward-looking statements include, among other things, statements regarding our expected net sales, GAAP earnings and adjusted earnings for the fourth quarter and full year 2013; our financial performance; our business plans and evolving business model; our positioning for revenue and earnings per share growth; our cost-savings and growth initiatives; and our restructuring program activities and expected impact. If our underlying assumptions turn out to be incorrect, or if certain risks or uncertainties materialize, actual results could vary materially from the expectations and projections expressed or implied by our forward-looking statements. These risks and uncertainties, in some cases, have affected and in the future could affect our ability to implement our business strategy and may cause actual results to differ materially from those contemplated by the statements expressed in this press release. As a result, readers are cautioned not to place undue reliance on any of our forward-looking statements.

Risks and uncertainties that may cause such differences include, among other things: future economic, political, competitive, reimbursement and regulatory conditions; new product introductions and the market acceptance of those products; markets for our products; expected pricing environment; expected procedural volumes; clinical trial results; demographic trends; intellectual property rights; litigation; financial market conditions; the execution and effect of our restructuring program; the execution and effect of our business strategy, including our cost-savings and growth initiatives; and future business decisions made by us and our competitors. New risks and uncertainties may arise from time to time and are difficult to predict. All of these factors are difficult or impossible to predict accurately and many of them are beyond our control. For a further list and description of these and other important risks and uncertainties that may affect our future operations, see Part I, Item IA - Risk Factors in our most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission, which we may update in Part II, Item 1A - Risk Factors in Quarterly Reports on Form 10-Q we have filed or will file hereafter. We disclaim any intention or obligation to publicly update or revise any forward-looking statement to reflect any change in our expectations or in events, conditions, or circumstances on which those expectations may be based, or that may affect the likelihood that actual results will differ from those contained in the forward-looking statements. This cautionary statement is applicable to all forward-looking statements contained in this press release.

#### **Use of Non-GAAP Financial Information**

A reconciliation of the company's non-GAAP financial measures to the corresponding GAAP measures, and an explanation of the company's use of these non-GAAP financial measures, is included in the exhibits attached to this news release.

CONTACT: Denise Kaigler

508-650-8330 (office) Corporate Affairs & Communications Boston Scientific Corporation media@bsci.com

Peter Lucht 508-650-8796 (office) Global Media Relations Boston Scientific Corporation media@bsci.com

Michael Campbell 508-650-8023 (office) Investor Relations Boston Scientific Corporation

BOSTON SCIENTIFIC CORPORATION
CONDENSED CONSOLIDATED GAAP RESULTS OF OPERATIONS
(Unaudited)

in millions, except per share data		onths Ended mber 30,	Nine Months Ended September 30,			
in millions, except per share data	2013	2012	2013	2012		
Net sales	\$ 1,735	\$ 1,735	\$ 5,305	\$ 5,428		
Cost of products sold	510	558	1,618	1,767		
Gross profit	1,225	1,177	3,687	3,661		
Operating expenses:						
Selling, general and administrative expenses	658	589	1,950	1,895		
Research and development expenses	217	220	644	648		
Royalty expense	28	29	115	125		
Amortization expense	101	99	305	294		
Goodwill impairment charge	_	748	423	4,350		
Intangible asset impairment charges	_	13	53	142		
Contingent consideration expense (benefit)	23	(20)	(18)	(9)		
Restructuring charges	19	54	55	93		
Gain on divestiture	_	(11)	(40)	(11)		
Litigation-related charges	76	50	206	119		
	1,122	1,771	3,693	7,646		
Operating income (loss)	103	(594)	(6)	(3,985)		
Other income (expense):						
Interest expense	(137)	(65)	(266)	(197)		
Other, net	(6)	(4)	(10)	23		
Income (loss) before income taxes	(40)	(663)	(282)	(4,159)		
Income tax expense (benefit)	(35)	1	(53)	(30)		
Net income (loss)	\$ (5)	\$ (664)	\$ (229)	\$ (4,129)		
Net income (loss) per common share - basic Net income (loss) per common share - assuming dilution	\$ (0.00) \$ (0.00)	\$ (0.48) \$ (0.48)	\$ (0.17) \$ (0.17)	\$ (2.91) \$ (2.91)		
Weighted-average shares outstanding Basic Assuming dilution	1,340.3 1,340.3	1,392.5 1,392.5	1,345.2 1,345.2	1,420.3 1,420.3		

BOSTON SCIENTIFIC CORPORATION
CONDENSED CONSOLIDATED BALANCE SHEETS

	As	s of
	September 30,	December 31,
in millions, except share data	2013	2012
	(Unaudited)	
ASSETS		
Current assets:		
Cash and cash equivalents	\$ 571	\$ 207
Trade accounts receivable, net	1,238	1,217
Inventories	895	884
Deferred income taxes	536	433
Prepaid expenses and other current assets	285	281
Total current assets	3,525	3,022
Property, plant and equipment, net	1,530	1,564
Goodwill	5,553	5,973
Other intangible assets, net	5,936	6,289
Other long-term assets	373	306
	\$ 16,917	\$ 17,154
LIABILITIES AND STOCKHOLDERS' EQUITY Current liabilities:		
Current debt obligations	\$ 3	\$ 4
Accounts payable	238	232
Accrued expenses	1,346	1,284
Other current liabilities	315	252
Total current liabilities	1,902	1,772

Long-term debt Deferred income taxes Other long-term liabilities	4,246 1,623 2,583	4,252 1,713 2,547
Commitments and contingencies		
Stockholders' equity		
Preferred stock, \$.01 par value - authorized 50,000,000		
shares, none issued and outstanding		
Common stock, \$.01 par value - authorized 2,000,000,000		
shares - issued 1,557,892,509 shares as of September 30,		
2013 and 1,542,347,188 shares as of December 31, 2012	16	15
Treasury stock, at cost - 219,056,477 shares as of September 30,		
2013 and 186,635,532 shares as of December 31, 2012	(1,367)	(1,092)
Additional paid-in capital	16,537	16,429
Accumulated deficit	(8,678)	(8,449)
Accumulated other comprehensive income (loss), net of tax	55	(33)
Total stockholders' equity	6,563	6,870
	\$ 16,917	\$ 17,154

#### **BOSTON SCIENTIFIC CORPORATION**

NON-GAAP NET INCOME AND NET INCOME PER COMMON SHARE RECONCILIATIONS (Unaudited)

Three Months Ended September 30, 2013 Tax Impact per diluted share in millions, except per share data Pre-Tax Impact (a) After-Tax GAAP net income (loss) (40)35 (5) (0.00)Non-GAAP adjustments: 30 28 Acquisition-related net charges (credits) (2)0.02 26 (8)18 0.01 Restructuring and restructuring-related net charges (b) 76 (19)57 0.04 Litigation-related net charges 70 (26)44 0.03 Debt extinguishment charges 101 88 0.07 Amortization expense (13)263 230 (33)Adjusted net income

	Three Months Ended September 30, 2012									
				Tax				npact per		
in millions, except per share data		Pre-Tax	Impact (a)		After-Tax		diluted share			
GAAP net income (loss)	\$	(663)	\$	(1)	\$	(664)	\$	(0.48)		
Non-GAAP adjustments:										
Goodwill impairment charge		748		_		748		0.54	**	
Intangible asset impairment charges		13		(3)		10		0.01	**	
Acquisition-related net charges (credits)		(20)		_		(20)		(0.01)	**	
Divestiture-related charges (credits)		(10)		2		(8)		(0.01)	**	
Restructuring and restructuring-related charges (c)		58		(19)		39		0.03	**	
Litigation-related net charges		50		(18)		32		0.02	**	
Discrete tax items		_		Ì		1		0.00	**	
Amortization expense		99		(16)		83		0.06	**	
Adjusted net income	\$	275	\$	(54)	\$	221	\$	0.16		

<sup>\*</sup> Assumes dilution of 23.6 million shares for the three months ended September 30, 2013 for all or a portion of these non-GAAP adjustments.

- (a) Amounts are tax effected at the Company's effective tax rate, unless the amount is a significant unusual or infrequently occurring item in accordance with FASB Accounting Standards Codification section 740-270-30, "General Methodology and Use of Estimated Annual Effective Tax Rate."
- (b) In the three months ended September 30, 2013, pre-tax restructuring charges were \$19 million and pre-tax restructuring-related charges were \$7 million recorded in selling, general and administrative expenses.
- (c) In the three months ended September 30, 2012, pre-tax restructuring charges were \$54 million and pre-tax restructuring-related charges were \$4 million, of which \$1 million was recorded in cost of products sold and \$3 million was recorded in selling, general and administrative expenses.

An explanation of our use of these non-GAAP financial measures is provided at the end of this document.

## **BOSTON SCIENTIFIC CORPORATION**

NON-GAAP NET INCOME AND NET INCOME PER COMMON SHARE RECONCILIATIONS

<sup>\*\*</sup> Assumes dilution of 6.8 million shares for the three months ended September 30, 2012 for all or a portion of these non-GAAP adjustments.

Nine Months	Ended Se	ptember 30.	2013
-------------	----------	-------------	------

in millions, except per share data	l ax Pre-Tax Impact (a) After-Tax							Impact per diluted share		
GAAP net income (loss)	\$	(282)	\$	53	\$	(229)	\$	(0.17)		
Non-GAAP adjustments:		` ,				` ,		` ,		
Goodwill impairment charge		423		(2)		421		0.31	*	
Intangible asset impairment charges		53		(8)		45		0.03	*	
Acquisition-related net charges (credits)		(5)		(3)		(8)		(0.01)	*	
Divestiture-related charges (credits)		(37)		12		(25)		(0.02)	*	
Restructuring and restructuring-related net charges (b)		`71 <sup>′</sup>		(20)		`51 <sup>′</sup>		0.04	*	
Litigation-related charges		206		(67)		139		0.10	*	
Debt extinguishment charges		70		(26)		44		0.03	*	
Amortization expense		305		(42)		263		0.20	*	
Adjusted net income	\$	804	\$	(103)	\$	701	\$	0.51		

Nine I	Months	Fnded	September 3	รก	2012

	-			Tax			In	npact per	
in millions, except per share data	Pre-Tax		Impact (a)		After-Tax		diluted share		
GAAP net income (loss)	\$	(4,159)	\$	30	\$	(4,129)	\$	(2.91)	
Non-GAAP adjustments:									
Goodwill impairment charges		4,350		(23)		4,327		3.05	**
Intangible asset impairment charges		142		(23)		119		0.09	**
Acquisition-related net charges (credits)		(41)		11		(30)		(0.02)	**
Divestiture-related charges (credits)		(7)		2		(5)		(0.00)	**
Restructuring and restructuring-related charges (c)		108		(32)		76		0.05	**
Litigation-related net charges		119		(47)		72		0.05	**
Discrete tax items		_		ÌÍ		1		0.00	**
Amortization expense		294		(45)		249		0.17	**
Adjusted net income	\$	806	\$	(126)	\$	680	\$	0.48	

<sup>\*</sup> Assumes dilution of 17.2 million shares for the nine months ended September 30, 2013 for all or a portion of these non-GAAP adjustments.

- (a) Amounts are tax effected at the Company's effective tax rate, unless the amount is a significant unusual or infrequently occurring item in accordance with FASB Accounting Standards Codification section 740-270-30, "General Methodology and Use of Estimated Annual Effective Tax Rate."
- (b) In the nine months ended September 30, 2013, pre-tax restructuring charges were \$55 million and pre-tax restructuring-related charges were \$16 million recorded in selling, general and administrative expenses.
- (c) In the nine months ended September 30, 2012, pre-tax restructuring charges were \$93 million and pre-tax restructuring-related charges were \$15 million, of which \$7 million was recorded in cost of products sold and \$8 million was recorded in selling, general and administrative expenses.

An explanation of our use of these non-GAAP financial measures is provided at the end of this document.

### **BOSTON SCIENTIFIC CORPORATION**

SEGMENT INFORMATION (Unaudited)

SEGMENT NET SALES*		Three Months Ended September 30,						Nine Months Ended September 30,					
in millions	2013		2012**	Change		2013		2012**	Change				
Interventional Cardiology	\$ 48		\$ 496	(2)%	\$	1,538	\$	1,646	(7)%				
Peripheral Interventions	20		188	7%		601		571	5%				
Cardiovascular	68	39	684	1%		2,139		2,217	(3)%				
Cardiac Rhythm Management	47	74	467	1%		1,445		1,466	(1)%				
Electrophysiology	3	35	35	(1)%		106		109	(3)%				
Rhythm Management	50	)9	502	1%		1,551		1,575	(2)%				
Endoscopy	33	31	308	8%		979		916	7%				
Urology/Women's Health	13	34	124	8%		378		367	3%				
Neuromodulation	11	6	88	32%		316		263	20%				
MedSurg	58	31	520	12%		1,673		1,546	8%				
Subtotal Core Businesses	1,77	79	1,706	4%		5,363		5,338	0%				
Divested Businesses		2	32	(95)%		56		91	(38)%				
Foreign Currency	(4	-6)	(3)	N/A		(114)		(1)	N/A				
Worldwide Net Sales	\$ 1,73	35	\$ 1,735	0%	\$	5,305	\$	5,428	(2)%				

<sup>\*\*</sup> Assumes dilution of 7.2 million shares for the nine months ended September 30, 2012 for all or a portion of these non-GAAP adjustments.

Growth rates are based on actual, non-rounded amounts and may not recalculate precisely.

SEGMENT OPERATING INCOME*	Three Months Ended September 30,					Nine Months Ended June 30,				
in millions		2013		2012**	_	2013		2012**		
Segment operating income										
Cardiovascular	\$	184	\$	175	\$	548	\$	561		
Rhythm Management		68		58		192		218		
MedSurg		187		169		521		452		
Operating income allocated to reportable segments		439		402	_	1,261		1,231		
Corporate expenses and currency exchange		(103)		(58)		(251)		(214)		
Goodwill and other intangible asset impairment charges; and acquisition-, divestiture-, restructuring-,										
and litigation-related charges and credits		(132)		(839)		(711)		(4,708)		
Amortization expense		(101)		(99)		(305)		(294)		
Operating income (loss)	\$	103	\$	(594)	\$	(6)	\$	(3,985)		

<sup>\*</sup>We measure and evaluate our reportable segments based on segment net sales and operating income, excluding the impact of changes in foreign currency and sales from divested businesses. Sales generated from reportable segments and divested businesses, as well as operating results of reportable segments and corporate expenses, are based on internally-derived standard currency exchange rates, which may differ from year to year, and do not include intersegment profits. We restated segment information for the prior period based on standard currency exchange rates used for the current period in order to remove the impact of foreign currency exchange fluctuations. We exclude from segment operating income certain corporate-related expenses and certain transactions or adjustments that our chief operating decision maker considers to be non-recurring and/or non-operational, such as amounts related to goodwill and other intangible asset impairment charges; acquisition-, divestiture-, restructuring- and litigation-related charges and credits; debt extinguishment charges; and amortization expense. Although we exclude these amounts from segment operating income, they are included in reported consolidated operating income (loss) and are included in the reconciliation above.

An explanation of the company's use of these non-GAAP financial measures is provided at the end of this document.

#### **BOSTON SCIENTIFIC CORPORATION**

WORLDWIDE CARDIAC RHYTHM MANAGEMENT (CRM) AND CORONARY STENT SYSTEM SALES (Unaudited)

#### **Three Months Ended September 30**

in millions	U	.S.	Intern	ational	Worl	dwide
	Q3 2013	Q3 2012	Q3 2013	Q3 2012	Q3 2013	Q3 2012
Defibrillator systems	\$ 212	\$ 205	\$ 118	\$ 122	\$ 330	\$ 327
Pacemaker systems	70	68	64	67	134	135
Total CRM products	\$ 282	\$ 273	\$ 182	\$ 189	\$ 464	\$ 462
in millions	U	.s.	Intern	ational	Worl	dwide
	Q3 2013	Q3 2012	Q3 2013	Q3 2012	Q3 2013	Q3 2012
During alusting atoms avestones	\$ 106	\$ 123	\$ 156	\$ 160	\$ 262	\$ 283
Drug-eluting stent systems						
Bare-metal stent systems	5	6	10	15	15	21

#### Nine Months Ended September 30

in millions		U.S.				International			Worldwide			
	Y	TD 2013	Ϋ́	ΓD 2012	Ϋ́	TD 2013	Ϋ́	TD 2012	Y	TD 2013	Υ	TD 2012
Defibrillator systems	\$	646	\$	655	\$	376	\$	395	\$	1,022	\$	1,050
Pacemaker systems		201		194		194		207		395		401
Total CRM products	\$	847	\$	849	\$	570	\$	602	\$	1,417	\$	1,451
in millions		U	.S.			Intern	atio	nal		Worl	dwi	de
in millions	– <del>-</del>	U TD 2013		TD 2012	<u> Y</u> 1	Intern		nal TD 2012	<u> </u>	Worl	-	de TD 2012
	- <u>Y</u>			<b>FD 2012</b> 439	<b>Y</b> 7				<u>Y</u>		-	
in millions  Drug-eluting stent systems Bare-metal stent systems	- <u>ү</u>	TD 2013	Ϋ́		<b>Y</b> 7	TD 2013	Υ٦	TD 2012		TD 2013	Υ	TD 2012

<sup>\*\*</sup> We have restated prior year information to conform to current year presentation.

# Q3 2013 Percentage change in BRIC Net Sales as compared to Q3 2012

	Change	Estimated	
	ported	Constant	Impact of
	ency	Currency	Foreign
Ва	sis	Basis	Currency
	28%	29%	(1)%

<sup>\*</sup>BRIC - Countries comprised of Brazil, Russia, India and China

#### **BOSTON SCIENTIFIC CORPORATION**

ESTIMATED NON-GAAP NET INCOME PER COMMON SHARE RECONCILIATIONS (Unaudited)

#### Q4 and Full Year 2013 EPS Guidance

	Q4 201	3 Estimate	Full Year 2013 Estimate				
	(Low)	(High)	(Low)	(High)			
GAAP results	\$ 0.04	\$ 0.08	\$ (0.13)	\$ (0.09)			
Goodwill impairment charge	_	_	0.31	0.31			
Intangible asset impairment charges	_	_	0.03	0.03			
Estimated acquisition-related net charges							
(credits)	0.02	0.02	0.01	0.01			
Estimated divestiture-related net credits	_	_	(0.02)	(0.02)			
Estimated restructuring-related charges	0.05	0.03	0.09	0.07			
Litigation-related charges	_	_	0.10	0.10			
Debt extinguishment charges	_	_	0.03	0.03			
Estimated amortization expense	0.07	0.07	0.27	0.27			
Adjusted results	\$ 0.18	\$ 0.20	\$ 0.69	\$ 0.71			

An explanation of our use of these non-GAAP financial measures is provided at the end of this document.

#### **Use of Non-GAAP Financial Measures**

To supplement our unaudited condensed consolidated financial statements presented on a GAAP basis, we disclose certain non-GAAP financial measures, including adjusted net income and adjusted net income per share that exclude certain amounts, and revenue growth rates that exclude the impact of changes in foreign currency exchange rates. These non-GAAP financial measures are not in accordance with generally accepted accounting principles in the United States.

The GAAP financial measure most directly comparable to adjusted net income is GAAP net income and the GAAP financial measure most directly comparable to adjusted net income per share is GAAP net income per share. To calculate revenue growth rates that exclude the impact of changes in foreign currency exchange rates, we convert actual net sales from local currency to U.S. dollars using constant foreign currency exchange rates in the current and prior period. The GAAP financial measure most directly comparable to this non-GAAP financial measure is growth rate percentages using net sales on a GAAP basis. Reconciliations of each of these non-GAAP financial measures to the corresponding GAAP financial measure are included in the accompanying schedules.

Management uses these supplemental non-GAAP financial measures to evaluate performance period over period, to analyze the underlying trends in our business, to assess our performance relative to our competitors, and to establish operational goals and forecasts that are used in allocating resources. In addition, management uses these non-GAAP financial measures to further its understanding of the performance of our operating segments. The adjustments excluded from our non-GAAP financial measures are consistent with those excluded from our operating segments' measures of net sales and profit or loss. These adjustments are excluded from the segment measures that are reported to our chief operating decision maker that are used to make operating decisions and assess performance.

We believe that presenting adjusted net income, adjusted net income per share, and revenue growth rates that exclude certain amounts and/or the impact of changes in foreign currency exchange rates, in addition to the corresponding GAAP financial measures, provides investors greater transparency to the information used by management for its financial and operational decision-making and allows investors to see our results "through the eyes" of management. We further believe that providing this information assists our investors in understanding our operating performance and the methodology used by management to evaluate and measure such performance.

The following is an explanation of each of the adjustments that management excluded as part of these non-GAAP financial measures for the three and nine months ended September 30, 2013 and 2012, and for the forecasted three month period and full year endingDecember 31, 2013, as well as reasons for excluding each of these individual items:

Adjusted Net Income and Adjusted Net Income per Share:

Goodwill and other intangible asset impairment charges- This amount represents (a) a non-cash write-down of our goodwill balance attributable to our global Cardiac Rhythm Management reporting unit in the first quarter of 2013; (b) non-cash write-downs of certain intangible asset balances in the second quarter of 2013; (c) a non-cash write-down of our goodwill balance attributable to our U.S. Cardiac Rhythm Management reporting unit in the third quarter of 2012; (d) a non-cash write-down of our goodwill balance attributable to our Europe, Middle East and Africa (EMEA) reporting unit in the second quarter of 2012; and (e) non-cash write-downs of certain intangible asset balances in the second and third quarters of 2012. We remove the impact of non-cash impairment charges from our operating performance to assist in assessing our cash generated from operations. We believe this is a critical metric for us in measuring our ability to generate cash and invest in our growth. Therefore, these charges are excluded from management's assessment of operating performance and are also excluded for purposes of calculating these non-GAAP financial measures to

facilitate an evaluation of our current operating performance and a comparison to our past operating performance, particularly in terms of liquidity.

Acquisition-related charges (credits) - These adjustments consist of (a) contingent consideration fair value adjustments, and (b) due diligence, other fees and exit costs. The contingent consideration adjustments represent accounting adjustments to state contingent consideration liabilities at their estimated fair value. These adjustments can be highly variable depending on the assessed likelihood and amount of future contingent consideration payments. Due diligence, other fees and exit costs include legal, tax, severance and other expenses associated with prior acquisitions that are not representative of on-going operations. Accordingly, management excluded these amounts for purposes of calculating these non-GAAP financial measures to facilitate an evaluation of our current operating performance and a comparison to our past operating performance.

<u>Divestiture-related expenses (gains)</u> - These amounts represent separation costs or recognized gains associated with the sale of our Neurovascular business in January 2011. Separation costs and gains on the sale represent those associated with the divestiture and are not representative of on-going operations. Accordingly, management excluded these amounts for purposes of calculating these non-GAAP financial measures to facilitate an evaluation of our current operating performance and a comparison to our past operating performance.

Restructuring and restructuring-related costs (credits) - These adjustments represent primarily severance and other direct costs associated with our 2011 Restructuring program. These costs are excluded by management in assessing our operating performance, as well as from our operating segments' measures of profit and loss used for making operating decisions and assessing performance. Accordingly, management excluded these costs for purposes of calculating these non-GAAP financial measures to facilitate an evaluation of our current operating performance and a comparison to our past operating performance.

<u>Litigation-related net charges</u> - These adjustments include certain significant product liability and other litigation-related charges and credits. These amounts are excluded by management in assessing our operating performance, as well as from our operating segments' measures of profit and loss used for making operating decisions and assessing performance. Accordingly, management excluded these amounts for purposes of calculating these non-GAAP financial measures to facilitate an evaluation of our current operating performance and a comparison to our past operating performance.

<u>Discrete tax items</u> - These items represent adjustments of certain tax positions, which were initially established in prior periods as a result of intangible asset impairment charges; acquisition-, divestiture-, restructuring- or litigation-related charges or credits. These adjustments do not reflect expected on-going operating results. Accordingly, management excluded these amounts for purposes of calculating these non-GAAP financial measures to facilitate an evaluation of our current operating performance and a comparison to our past operating performance.

<u>Debt extinguishment charges</u> - This item represents premiums, accelerated amortization of debt issuance costs and investor discount costs net of interest rate hedge gains related to the early extinguishment of \$1.450 billion of debt during the third quarter of 2013. These adjustments are not expected to recur and do not reflect expected on-going operating results. Accordingly, management excluded these amounts for purposes of calculating these non-GAAP financial measures to facilitate an evaluation of our current operating performance and a comparison to our past operating performance.

Amortization expense - Amortization expense is a non-cash expense and does not impact our liquidity or compliance with the covenants included in our credit facility agreement. Management removes the impact of amortization from our operating performance to assist in assessing our cash generated from operations. We believe this is a critical metric for measuring our ability to generate cash and invest in our growth. Therefore, amortization expense is excluded from management's assessment of operating performance and is also excluded from the measures management uses to set employee compensation. Accordingly, management has excluded amortization expense for purposes of calculating these non-GAAP financial measures to facilitate an evaluation of our current operating performance, particularly in terms of liquidity.

Revenue Growth Rates Excluding the Impact of Changes in Foreign Currency Exchange Rates

Changes in foreign currency exchange rates - The impact of changes in foreign currency exchange rates is highly variable and difficult to predict. Accordingly, management excludes the impact of changes in foreign currency exchange rates for purposes of reviewing revenue growth rates to facilitate an evaluation of our current operating performance and a comparison to our past operating performance.

Adjusted net income, adjusted net income per share and revenue growth rates that exclude certain amounts and/or the impact of changes in foreign currency exchange rates are not in accordance with U.S. GAAP and should not be considered in isolation from or as a replacement for the most directly comparable GAAP financial measures. Further, other companies may calculate these non-GAAP financial measures differently than we do, which may limit the usefulness of those measures for comparative purposes.

SOURCE Boston Scientific Corporation

https://news.bostonscientific.com/2013-10-24-Boston-Scientific-Announces-Results-For-Third-Quarter-Ended-September-30-2013